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Our previous studies have demonstrated that the total ﬂavonoids (XBXT-2) isolated from the extract of Xiaobuxin-Tang (XBXT),
a traditional Chinese herbal decoction, ameliorated behavioral alterations and hippocampal dysfunctions in chronically stressed
rats. Studies over the last decades have suggested that the hyperactivity of hypothalamic-pituitary-adrenal (HPA) axis is one of
the most consistent ﬁndings in stress-related depression. Herein, we used the same chronic mild stress model of rats as before to
further investigate the eﬀect of XBXT-2 on the hyperactivity of HPA axis, including the stress hormones levels and glucocorticoid
receptors (GRs) expression. Our ELISA results showed that chronic administration of XBXT-2 (25, 50mgkg−1, p.o., 28 days,
the eﬀective doses for behavioral responses) signiﬁcantly decreased serum corticosterone level and its upstream stress hormone
adrenocorticotropic hormone (ACTH) level in chronically stressed rats. Furthermore, western blotting result demonstrated
XBXT-2 treatment ameliorated stress-induced decrease of GRs expression in hippocampus, an important target involved in the
hyperactivity of HPA axis. These results were similar to that of classic antidepressant imipramine treatment (10mgkg−1, p.o.). In
conclusion,themodulationofHPAaxisproduced byXBXT-2,includingtheinhibitionofstresshormoneslevelsandup-regulation
of hippocampal GRs expression, may be an important mechanism underlying its antidepressant-like eﬀect in chronically stressed
rats.
1.Introduction
Nowadays, depression with increasing morbidity and mor-
tality has become a big health problem to the whole world.
Hypothalamic-pituitary-adrenal (HPA) axis, an important
neuroendocrine system, has been evidenced as a key struc-
ture in the pathophysiology of depression/stress disorder.
Studiesoverthelastdecadeshaveshownthathyperactivityof
HPA axis is the main biochemical change, besides disturbed
monoaminergic neurotransmission, observed in patients
suﬀering from major depression [1, 2].
Recently, accumulating studies have showed that herb
preparations may provide us a prospective alternative in the
treatment of depression for their better compliance and low-
er side eﬀects, such as l-Perillaldehyde (a major component
in Perillae Herba) featured by Ito et al. [3], Chaihu-Shugan-
San by Kim et al. [4], Banxia-houpu decoction by Li and
his colleague [5], and preparations from St John’s wort
extracts reviewed by M¨ uller [6], but more attention is still
needed in this ﬁeld for deeper and more thorough scientiﬁc
research.
Xiaobuxin-Tang (XBXT), a traditional Chinese herbal
decoction, which contains Haematitum, Flos Inulae, Folium
Phyllostachydis Henonis and Semen Sojae Preparatum, four
Chinese traditional medicines, was recorded in the silk scroll
manuscript of “Fuxinjue Zangfu Yongyao Fayao”, written
1000 years ago. Our previous studies have demonstrated that
the total ﬂavonoids (XBXT-2) extracted from Xiaobuxin-
Tang (XBXT) exerted potent antidepressant-like eﬀects in
multiple animal models of depression [7]. Furthermore,2 Evidence-Based Complementary and Alternative Medicine
recent studies in our laboratory showed that XBXT-2 (25,
50mg/kg, p.o., 28 days) could reverse the behavioral
alterations and hippocampal dysfunctions in chronically
stressed rats, suggesting XBXT-2 may exert signiﬁcant an-
tidepressant-like eﬀect in chronically stressed rats and the
maintenance of hippocampal morphologic and functional
plasticity may be involved in it [8, 9]. However, until now,
we know nothing about the eﬀect of XBXT-2 on HPA axis in
chronic mild stress (CMS) model.
Glucocorticoids (cortisol in humans and corticosterone
in rodents), the hormonal end-product of the HPA axis,
are hypersecreted in depression/stress disorder, which is one
of the most consistent ﬁndings in both clinical patients
and animal models [1, 2, 10]. Moreover, the upstream
stress hormone of glucocorticoids, adrenocorticotropic hor-
mone (ACTH), which is responsible for the release and
regulation of glucocorticoids, is also elevated in depressed
patients. For example, a signiﬁcant percentage of depressed
patients have increased levels of cortisol in the saliva,
serum, urine and cerebrospinal ﬂuid, as well as abnormal
24 h pattern of cortisol and ACTH secretion [11–13].
Similarly, in experimental animals, chronic stress paradigms
can recapitulate not only many behavioral characteristics
but also lots of biochemical states of depression including
elevated corticosterone and ACTH levels [14, 15]. And these
alterations can be normalized by most therapeutic agents in
clinic, which is in line with their antidepressant response
[16, 17].
Besides the elevated stress hormones, the hyperactiv-
ity of HPA axis in stress/depression disorder is particu-
larly thought to be related to reduced feedback inhibi-
tion by endogenous glucocorticoids. Recently, accumulating
studies have indicated glucocorticoid receptors (GRs), one
type of glucocorticoids cognate receptors, through which
endogenous glucocorticoids serve as potent negative regu-
lators of HPA axis activity, is one of the most important,
striking and innovative targets in the pathophysiology
and therapy of depression [18–20]. Clinical ﬁndings have
shown that the number of GRs in CNS was reduced in
depressed patients and this might, at least partly, account
for the impaired feedback inhibition in HPA axis [21].
A recent research reported transgenic mouse strains that
under-express GRs displayed depressive-like behaviors [22].
Furthermore, hippocampus, as an important limbic brain
section regulating mood and cognitive functions, has long
beenconsideredasanessentialregulatorinHPAaxisnegative
feedback. Experimental data support the idea that chronic
treatment with most successful antidepressant increase the
GRs mRNA or GRs protein level in rat hippocampus [23–
26].
Considering the crucial role of HPA axis in the patho-
physiology and therapy of stress-induced depression, in the
present study, we used CMS model, a paradigm causing
prolonged HPA axis hyperactivity, to investigate whether
chronic XBXT-2 (25, 50mgkg−1, p.o., the eﬀective doses
for behavioral responses) administration could decrease the
elevated corticosterone and ACTH levels induced by stress,
and also, we assessed the eﬀect of XBXT-2 on hippocampal
GRs expression in chronically stressed rats.
2.Methods
2.1. Preparation of the Total Flavonoids from
Xiaobuxin-Tang sExtract
2.1.1. Materials. Traditional Chinese medicines Haemati-
tum, Flos Inulae, Folium Phyllostachydis Henonis and Se-
men Sojae Preparatum were purchased from Beijing Ton-
grentang Drugstore (Beijing, China) and were identiﬁed
by Prof. Lian-Sheng Shen, School of Chinese medicine,
Beijing University of Chinese Medicine as calcined product
of Ochery hematite, ﬂowers of Inula japonica Thunb., leafs
of Phyllostachys nigra (Lodd.) Munro var. henonis (Mitf.)
Stapf ex Rendle, fermented product of Glycine max (L.)
Merr., respectively. The voucher specimens (No. 02002, No.
02003, No. 02004, No. 02005, respectively) are deposited
in the Laboratory of Phytochemistry, Beijing Institute of
Pharmacology and Toxicology, China.
2.1.2. Extraction. The medicines Haematitum, Flos Inulae,
Folium Phyllostachydis Henonis and Semen Sojae Prepara-
tum (2:2:1:1, w/w) (6kg) were mixed and extracted three
times with 70% alcohol at 100◦C. The combined extracts
were ﬁltered and evaporated by a rotary evaporator under
reducedpressuretoobtainaviscousalcoholicextract(784g),
which was dispersed in 1l water and partitioned with
petroleumether.Subsequently,thewaterfractionwasdiluted
with 4l water and the water solution was centrifuged at
1560g for 30min. Then, the solution was passed by column
chromatography on AB-8 macroporous resin (7l). After
eluting with 14l water, the column was eluted with 21 l
70% alcohol and the 70% alcohol elution was evaporated
and dried in vacuo to obtain the total ﬂavonoids (320g).
Using lutin as standard, the apparent ﬂavone content of the
extract was determined as 76.03% by colorimetric method
[27].
2.2. Animals. Sprague Dawley rats weighing 180–220g (Bei-
jing Vital Laboratory Animal Technology Company, Beijing,
China) were used for the experimental procedure. The
animals were group housed in polypropylene cages under
standard experimental conditions: room temperature 21 ±
2◦C, humidity 40–60%, 12h:12h light/dark cycle (lights
on at 8:00a.m.). Food and water were available ad libitum.
Animals were allowed to have a period of acclimation before
any experiment. All animal experiments were carried out in
accordance with the National Institute of Health Guide for
the Care and Use of Laboratory Animals (NIH publication
No. 86-23, revised 1996).
2.3. Drugs and Reagents. Imipramine hydrochloride (IMI)
was purchased from Sigma (St Louis, MO, USA). Rabbit
anti-GR (α + β) and rabbit anti-β-actin antibodies were
purchased from Santa CruzBiotechnology (CA,USA).HRP-
conjugated goat anti-rabbit IgG antibody was purchased
from Zhongshan Technology (Beijing, China). Rat ELISA
KIT for corticosterone and ACTH were purchased from TPI
Inc (WA, USA).Evidence-Based Complementary and Alternative Medicine 3
Enviroment
acclimatization Sucrose training
Sucrose
preference
test
CMS start
Open ﬁeld SP-test again
Week
Day
Day
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Sunday
Food
deprivation
Water
deprivation
Restricted
food
Empty
bottles
Paired
housing
Cage tilt
Overnight
illumination
Soiled cage Stroboscope White noise
Forced
swimming
Restraint
−3 −2 01234
0 7 14 21 28
5
NFS
15:00 15:00
10:00
10:00
10:00
10:00
10:00
10:00
10:00 10:00
9:00
9:00
9:00
9:00
9:00
9:00 9:00
20:00
17:00
8:00 8:00
8:00 8:00
8:00
8:00
8:00
Figure 1: An outline of the design for the experiment (top: with time course for CMS and post-CMS tests; bottom: CMS protocol).
2.4. CMS Procedure. The stress procedure performed here
mainly referred to Grønli et al. [28] and Willner [29]w i t h
some modiﬁcations. The stressed groups were exposed to
the following stressors for four consecutive weeks: (i) food
or water deprivation; (ii) restricted access to food; (iii)
exposure to empty water bottles following a period of water
deprivation; (iv) paired housing; (v) cage tilt (45◦); (vi)
overnightillumination;(vii)soiledcage(200mlwaterspilled
onto 100g sawdust bedding); (viii) stroboscopic lighting
(100 ﬂashes/min); (ix) white noise (∼110dB); (x) forced
swimming (water temperature 15◦C, 5min); (xi) Restraint.
The stress procedure in the ﬁrst week was presented in
Figure 1 and repeated with unpredictable sequence during
the following 3 weeks. Animals in control group were
left undisturbed in the home cages in a separate room.
Except “control” group, we divided stressed rats into “stress-
vehicle”, “stress-IMI” and “stress-XBXT-2” groups, which
received distilled water, IMI (10mgkg−1) and XBXT-2 (25
or 50mgkg−1), respectively. Each group included eight
rats. Drugs (including distilled water) were given orally
once a day at 8:00–9:00 a.m. from the beginning of stress
regime.
2.5. Enzyme-Linked ImmunoSorbent Assay. On the 8th day
after the end of stress procedure, the rats were decapitated.
Blood was sampled, centrifuged (860g, 20min) at 4◦Ca n d
then stored at −20◦C. Serum corticosterone and ACTH
concentrations were detected by Enzyme Immunoassay
(magnetic solid phase) kits (TPI Inc, WA, USA). According
to the manufacturer’s; protocol, samples (or standard) and
conjugate were added to each well, respectively, and then the
plate was incubated for 1h at room temperature without
blocking. After several times washing and proper color
development, the optical density value was read at 450
nm in ELISA plate reader. The sensitivity of the assay
for corticosterone and ACTH was 0.7nmol/l and 1pg/ml,
respectively.
2.6. Western Blotting. Following decapitation,rat hippocam-
pus were isolated rapidly and stored at −80◦Cf o rw e s t e r n
blotting detection. The tissues were weighed, sonicated in
RIPAlysisbuﬀersupplementedwithfresh proteaseandphos-
phatase inhibitors, and centrifuged at 13800g for 25min.
Then the protein concentration was determined by BCA
assay. After denaturation and electrophoresis, the proteins4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀect of XBXT-2 on the serum corticosterone level in
chronically stressed rats. Serum corticosterone concentration was
detected using a commercial ELISA kit. Each column represents
as the mean ± SEM, n = 8. ∗∗P < .01 compared with control-
vehicle; ##P < .01 compared with stress-vehicle (ANOVA followed
by Newmann-Kuels tests).
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Figure 3:Eﬀect ofXBXT-2on the serum ACTH level in chronically
stressed rats. Serum ACTH concentration was detected using a
commercial ELISA kit. Each column represents as the mean ±
SEM, n = 8. ∗∗∗P < .001 compared with control-vehicle; ###P <
.001compared withstress-vehicle (ANOVAfollowedby Newmann-
Kuels tests).
were transferred onto a NC membrane in semi-dry condi-
tions. Following blocking in 1% BSA for 2h, the protein
membrane was incubated in primary antibody rabbit anti-
GR (1:1000) at 4◦C overnight and then in secondary anti-
body HRP-conjugated goat anti-rabbit IgG (1:5000) for 1h.
ECL + kit (APPLYGEN Company, Beijing, China) was used
forthedetectionof proteinband andthechemiluminescence
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Figure 4: Eﬀect of XBXT-2 on hippocampal GRs expression in
chronically stressed rats. The intensity of western bands was quan-
tiﬁed with a densitometric scanner. Each column represents as the
mean ± SEM, n = 5. Band 1: control + vehicle; Band 2: stress +
vehicle; Band 3: stress + IMI (10mg/kg, p.o.); Band 4: stress +
XBXT-2 (25mg/kg, p.o.); Band5: stress + XBXT-2 (50mg/kg, p.o.);
∗∗∗P < .001 compared with control-vehicle, ##P < .01 compared
with stress-vehicle (ANOVA followed by Newmann-Kuels tests).
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2.7. Statistics. All data were expressed as mean ± SEM and
analyzed by one-way analysis of variance (ANOVA) followed
by Newmann-Kuels tests for inter-group comparisons. A
value of P<. 05 was considered statistically signiﬁcant.Evidence-Based Complementary and Alternative Medicine 5
3.Results
3.1. Reduction of Serum Corticosterone and ACTH Concen-
tration in CMS Rats. ELISA analysis demonstrated that 28-
day stress exposure signiﬁcantly increased the serum corti-
costerone concentration in rats by 110.38% (P<. 01, versus
control-vehicle). Chronic XBXT-2 (25, 50mgkg−1, p.o.) or
IMI (10mgkg−1, p.o.) treatment, as shown in Figure 2,
attenuated this alteration and decreased serum corticos-
terone concentration by 56.89%, 40.47% and 40.04%,
respectively (F(4,35) = 16.77, P<. 01 versus stress-vehicle).
As shown in Figure 3, serum ACTH concentration was
signiﬁcantlyincreasedinchronicallystressed ratsby198.03%
compared with control (P < .001). In line with its eﬀect
on corticosterone concentration, chronic XBXT-2 (25,
50mgkg−1, p.o.) administration reversed this change and
reduced the ACTH concentration by 53.38% and 51.01%,
respectively (P < .001 versus stress-vehicle). Similar result
was observed in IMI group (P < .001 versus stress-vehicle).
These two results indicated that chronic XBXT-2 treat-
ment signiﬁcantly decreased the stress hormones (corticos-
terone and ACTH) levels, which were remarkably elevated by
the stress regime.
3.2. Up-Regulation of Hippocampal GRs Expression in CMS
Rats. Western blotting analysis (Figure 4) showed that the
total GRs expression in hippocampus were decreased by 28
day stress regime (P < .001 versus control-vehicle). While
chronic XBXT-2 (25, 50mgkg−1, p.o.) or IMI (10mgkg−1,
p.o.) administration signiﬁcantly increased hippocampal
GRs expression [F(4,20) = 9.618, P < .01 versus stress-
vehicle].
4.Discussion
Ourpreviousworkhaveshownthatthe28-dayunpredictable
stress paradigm induced a series of depressive-like behaviors
in rats, including reduced sucrose preference, deﬁcient
locomotor activity, prolonged latency to novelty-suppressed
feeding and weight loss, which were consistent with many
previous reports [8, 15, 29, 30], and chronic XBXT-2 (25,
50mgkg−1, p.o., 28 days) treatment signiﬁcantly reversed
these alterations, and also in present study we got similar
behavioral results as before (not listed). Furthermore, we
found that the stress hormones including corticosterone and
ACTH levels in rats were signiﬁcantly increased by chronic
stress exposure, as well as the decreased hippocampal GRs
expression, which together manifested the hyperactivity and
impaired feedback inhibition of HPA axis in chronically
stressed rats.Similar tothebehavioraleﬀects,chronic XBXT-
2a td o s eo f2 5o r5 0 m g k g −1 (p.o.) treatment signif-
icantly attenuated serum hormones levels and increased
GRs expression in hippocampus. Based on these data, the
authors conclude that the eﬀect of XBXT-2 exerted on the
stress-induced HPA axis hyperactivity may be an important
mechanism underlying its antidepressant-like eﬀects.
As evidenced by enormous studies, hyperactivity of
HPA axis, which is commonly seen in depressed patients,
could be reversed during clinically eﬀective therapies with
antidepressant drugs [2, 17]. Moreover, among a multitude
of molecular events, the stress hormones levels and hip-
pocampal GRs number are two important targets by which
antidepressant drugs may exert their clinical eﬀects [16, 31].
Stress—a well-known environmental factor capable of
precipitating or exacerbating depressive episodes in hu-
mans—is also a strong trigger of HPA axis activation [32].
The HPA axis, as the name implies, consists of a feedback
loop including the hypothalamus, pituitary and adrenal
glands. Brieﬂy, the hypothalamus releases corticotropin-
releasing hormone and arginine vasopressin in response to
a stressor, which in turn activate the secretion of ACTH
from the pituitary, which ﬁnally stimulates the secretion of
cortisol (in humans) or corticosterone (in rodents) from
the adrenal cortex. As observed in our experiment, 28-
day stress signiﬁcantly increased serum corticosterone and
ACTH levels in rats, accompanied by the depressive-like
behavioral alterations (not list, similar as [8]), while XBXT-2
(25, 50mg kg−1, p.o., 28 days) administration signiﬁcantly
decreased the elevated serum corticosterone and ACTH
levels, which may account for a primary neuroendocrine
mechanism underlying its behavioral eﬀects.
Hippocampus, known to contain high density of GRs, is
the key structure in the inhibition of stressed-induced HPA
axis activation, and also more sensitive to glucocorticoid-
mediated impairment [31, 33]. Indeed, it has been suggested
that prolonged overproduction of glucocorticoids, whether
as a result of ongoing stress or a genetic predisposition
to HPA axis hyperactivity, damages GRs, especially in the
hippocampuswhich isessentialforHPAaxisrestraint, andin
turn reduces GR-mediated negative feedback by endogenous
glucocorticoids, which, on the other hand, promotes the
sustaining hypersecretion of glucocorticoids (this process is
also known as the glucocorticoid cascade hypothesis) [2].
In animals, chronic stress paradigms have been evidenced to
down-regulate hippocampal GRs number [34, 35]. Likely, in
the present study, we found the hippocampal GRs expression
in rats was signiﬁcantly reduced by chronic stress procedure,
in another word, impaired by the oversecretion of corticos-
terone, and chronic XBXT-2 treatment reversed this change,
which may account for a more profound neuroendocrine
mechanism underlying its behavioral eﬀects.
In mammals, the HPA axis and the 5-HT system are
closely interacted in CNS (particularly in hippocampus) and
greatly involved in stress-related disorders [36, 37]. Given
that 5-HT in hippocampus is highly sensitive to glucocorti-
coids,itis notsurprising thatchronic hypercortisolism could
cause dysfunction of 5-HT nervous system especially in hip-
pocampus[38].In ourpreviouswork, wehavedemonstrated
that chronic XBXT-2 administration signiﬁcantly increased
hippocampal 5-HT and its metabolite 5-hydroxyindoleacetic
acid levels in chronically stressed rats [8]. Therefore, it could
be speculated that the amelioration XBXT-2 produced on
the monoaminergic system may be associated with its eﬀect
on HPA axis. Meanwhile, extensive literature have shown
that hyperactivity of HPA axis or sustaining hypersecretion
of glucocorticoids may result in hippocampal atrophy in
major depression, including dendritic shrinkage, impaired
neurogenesis and deﬁcient neurotrophic factors [39–41].6 Evidence-Based Complementary and Alternative Medicine
Studies in our laboratory have shown that chronic XBXT-
2 treatment increased hippocampal neurogenesis, and also
hippocampal BDNF and pCREB (Ser133) expression in
chronically stressed rats [9]. Accordingly, it seems that the
beneﬁcialeﬀectsthatXBXT-2producedonthehippocampus
may, at least partly, arise from its regulation on the hyper-
activity of HPA axis. Taken together, the aforementioned
mechanisms produced by XBXT-2 are not contradictory, but
supported and connected with each other (Figure 5). Brieﬂy,
in the authors’ point of view, XBXT-2 played a signiﬁcant
role in the modulation of HPA axis function, which may
be an important and essential mechanism underlying its
antidepressant-like eﬀects in chronic stress model of rats.
Acknowledgment
This work was supported by the National Natural Sci-
ence Foundation of China (No. 30400600, 30901975);
the National Basic Research Program of China (No.
2007CB512307);andtheNationalHighTechnologyResearch
and Development Program of China (No. 2007AA02Z424).
References
[1] M. F. Juruena, A. J. Cleare, and C. M. Pariante, “The hypotha-
lamic pituitary adrenal axis, glucocorticoid receptor function
and relevance to depression,” Revista Brasileira de Psiquiatria,
vol. 26, no. 3, pp. 189–201, 2004.
[2] C. M. Pariante and S. L. Lightman, “The HPA axis in major
depression: classical theories and new developments,” Trends
in Neurosciences, vol. 31, no. 9, pp. 464–468, 2008.
[ 3 ]N .I t o ,T .N a g a i ,T .O i k a w a ,H .Y a m a d a ,a n dT .H a n a w a ,
“Antidepressant-like eﬀect of l-perillaldehyde in stress-
induced depression-like model mice through regulation of
theolfactorynervoussystem,”Evidence-Based Complementary
and Alternative Medicine, 2008.
[4] S.-H. Kim, J. Han, D.-H. Seog et al., “Antidepressant eﬀect of
Chaihu-Shugan-San extract and its constituents in rat models
of depression,” Life Sciences, vol. 76, no. 11, pp. 1297–1306,
2005.
[ 5 ]J . - M .L i ,L . - D .K o n g ,Y . - M .W a n g ,C .H .K .C h e n g ,W . - Y .
Zhang, and W.-Z. Tan, “Behavioral and biochemical studies
on chronic mild stress models in rats treated with a Chi-
nese traditional prescription Banxia-houpu decoction,” Life
Sciences, vol. 74, no. 1, pp. 55–73, 2003.
[ 6 ]W .E .M¨ uller, “Current St. John’s wort research from mode of
action to clinical eﬃcacy,” Pharmacological Research, vol. 47,
no. 2, pp. 101–109, 2003.
[7] Y.-Z. Zhang, N.-J. Yu, L. Yuan et al., “Antidepressant eﬀect
of total ﬂavonoids extracted from Xiaobuxin-Tang in forced
swimming tests and learned helplessness in rats and mice,”
Chinese Journal of Pharmacology and Toxicology, vol. 22, no.
1, pp. 1–8, 2008.
[8] L. An, Y.-Z. Zhang, N.-J. Yu et al., “Role for serotonin in the
antidepressant-like eﬀect of a ﬂavonoid extract of Xiaobuxin-
Tang,” Pharmacology Biochemistry and Behavior, vol.89,no. 4,
pp. 572–580, 2008.
[ 9 ]L .A n ,Y .Z .Z h a n g ,N .J .Y u ,X .M .L i u ,N .Z h a o ,a n d
L. Yuan, “The total ﬂavonoids extracted from Xiaobuxin-
Tang up-regulate the decreased hippocampal neurogenesis
and neurotrophic molecules expression in chronicallystressed
rats,” Progress in Neuro-Psychopharmacology and Biological
Psychiatry, vol. 32, pp. 1484–1490, 2008.
[10] I. Heuser, “The hypothalamic-pituitary-adrenal system in
depression,” Pharmacopsychiatry, vol. 31, no. 1, pp. 10–13,
1998.
[ 1 1 ]P .L i n k o w s k i ,J .M e n d l e w i c z ,R .L e C l e r c ,M .B r a s s e u r ,P .
Hubain, and J. Goldstein, “The 24-hour proﬁle of ACTH
and cortisol in major depressive illness,” Journal of Clinical
Endocrinology and Metabolism, vol. 61, pp. 429–438, 1985.
[12] C. HeimandC. B.Nemeroﬀ,“Neurobiologyofearlylifestress:
clinical studies,” Seminars in Clinical Neuropsychiatry,v o l .7 ,
no. 2, pp. 147–159, 2002.
[13] B. Weber, S. Lewicka, M. Deuschle, M. Colla, P. Vecsei, and I.
Heuser, “Increaseddiurnalplasmaconcentrationsofcortisone
in depressed patients,” Journal of Clinical Endocrinology and
Metabolism, vol. 85, no. 3, pp. 1133–1136, 2000.
[14] V. Butterweck, M. Hegger, and H. Winterhoﬀ, “Flavonoids of
St. John’s Wort reduce HPA axis function in the rat,” Planta
Medica, vol. 70, no. 10, pp. 1008–1011, 2004.
[15] P. Willner, “Chronic mild stress (CMS) revisited: consistency
and behavioural-neurobiologicalconcordance in the eﬀects of
CMS,” Neuropsychobiology, vol. 52, no. 2, pp. 90–110, 2005.
[16] J. P. Brouwer, B. C. Appelhof, E. F. C. van Rossum et
al., “Prediction of treatment response by HPA-axis and
glucocorticoid receptor polymorphisms in major depression,”
Psychoneuroendocrinology, vol. 31, no. 10, pp. 1154–1163,
2006.
[17] F.HolsboerandN.Barden,“Antidepressants andhypothalam-
ic-pituitary-adrenocortical regulation,” Endocrine Reviews,
vol. 17, no. 2, pp. 187–205, 1996.
[18] B.L.MasonandC.M.Pariante,“Theeﬀectsofantidepressants
on the hypothalamic-pituitary-adrenal axis,” Drug News and
Perspectives, vol. 19, no. 10, pp. 603–608, 2006.
[19] C. M. Pariante, “The glucocorticoid receptor: part of the solu-
tion or part of the problem?” Journal of Psychopharmacology,
vol. 20, no. 4, pp. 79–84, 2006.
[20] F. Thomson and M. Craighead, “Innovative approaches
for the treatment of depression: targeting the HPA axis,”
Neurochemical Research, vol. 33, no. 4, pp. 691–707, 2008.
[ 2 1 ]M .J .W e b s t e r ,M .B .K n a b l e ,J .O ’ G r a d y ,J .O r t h m a n n ,a n d
C. S. Weickert, “Regional speciﬁcity of brain glucocorticoid
receptor mRNA alterationsinsubjects withschizophrenia and
mood disorders,” Molecular Psychiatry, vol. 7, no. 9, pp. 985–
994, 2002.
[22] S. Chourbaji, M. A. Vogt, and P. Gass, “Mice that under- or
overexpress glucocorticoid receptors as models for depression
or posttraumatic stress disorder,” Progress in Brain Research,
vol. 167, pp. 65–77, 2008.
[23] B. Budziszewska, J. Siwanowicz, and E. Przegalinski, “The
eﬀect of chronic treatment with antidepressant drugs on the
corticosteroid receptor levels in the rat hippocampus,” Polish
Journal of Pharmacology, vol. 46, no. 3, pp. 147–152, 1994.
[24] A. Peiﬀer, S. Veilleux, and N. Barden, “Antidepressant and
other centrally acting drugs regulate glucocorticoid receptor
messenger RNA levels in rat brain,” Psychoneuroendocrinology,
vol. 16, pp. 505–515, 1991.
[25] E. Przegali˜ nski, B. Budziszewska, J. Siwanowicz, and L.
Jaworska, “The eﬀect of repeated combined treatment with
nifedipine and antidepressant drugs or electroconvulsive
shock on the hippocampal corticosteroid receptors in rats,”
Neuropharmacology, vol. 32, pp. 1397–1400, 1993.
[26] J. R. Seckl and G. Fink, “Antidepressants increase glucocorti-
coid and mineralocorticoid receptor mRNA expression in ratEvidence-Based Complementary and Alternative Medicine 7
hippocampus in vivo,” Neuroendocrinology,v o l .5 5 ,n o .6 ,p p .
621–626, 1992.
[27] G.Xu,H.Zhang,andJ.Hu,“Leachingmethodofﬂavonefrom
bamboo leaves,” Fenxi Huaxue, vol. 28, no. 7, pp. 857–859,
2000.
[28] J. Grønli, R. Murison, E. Fiske et al., “Eﬀects of chronic mild
stressonsexualbehavior,locomotoractivityandconsumption
of sucrose and saccharine solutions,” Physiology and Behavior,
vol. 84, no. 4, pp. 571–577, 2005.
[29] P. Willner, “Validity, reliability and utility of the chronic mild
stress model of depression: a 10-year review and evaluation,”
Psychopharmacology, vol. 134, no. 4, pp. 319–329, 1997.
[30] B. Vollmayr and F. A. Henn, “Stress models of depression,”
Clinical Neuroscience Research, vol. 3, no. 4-5, pp. 245–251,
2003.
[31] B. Budziszewska, “Eﬀect of antidepressant drugs on the
hypothalamic-pituitary-adrenal axis activity and glucocorti-
coid receptor function,” Polish Journal of Pharmacology,v o l .
54, no. 4, pp. 343–349, 2002.
[32] C. Pittenger and R. S. Duman, “Stress, depression, and
neuroplasticity: a convergence of mechanisms,” Neuropsy-
chopharmacology, vol. 33, no. 1, pp. 88–109, 2008.
[33] P. J. Lucassen, M. B. M¨ uller, F. Holsboer et al., “Hippocampal
apoptosis in major depression is a minor event and absent
from subareas at risk for glucocorticoid overexposure,” Amer-
ican Journal of Pathology, vol. 158, no. 2, pp. 453–468, 2001.
[34] K. Mizoguchi, M. Yuzurihara, A. Ishige, H. Sasaki, D.-H.
C h u i ,a n dT .T a b i r a ,“ C h r o n i cs t r e s sd i ﬀerentially regulates
glucocorticoid negative feedback response in rats,” Psychoneu-
roendocrinology, vol. 26, no. 5, pp. 443–459, 2001.
[ 3 5 ]M .E .P a s k i t t i ,B .J .M c C r e a r y ,a n dJ .P .H e r m a n ,“ S t r e s s
regulation of adrenocorticosteroid receptor gene transcription
and mRNA expression in rat hippocampus: time-course
analysis,”Brain Research.MolecularBrain Research,vol.80,pp.
142–152, 2000.
[36] W. J. Cubała and J. Landowski, “Serotoninergic system and
limbic-hypothalamic-pituitary-adrenal axis (LHPA axis) in
depression,” Psychiatria Polska, vol. 40, no. 3, pp. 415–430,
2006.
[37] L.Lanf u mey ,R .M ong e au ,C .C ohe n- Salmon,andM.H amon,
“Corticosteroid-serotonin interactions in the neurobiological
mechanisms of stress-related disorders,” Neuroscience and
Biobehavioral Reviews, vol. 32, no. 6, pp. 1174–1184, 2008.
[ 3 8 ]H .T a k e d a ,M .T s u j i ,a n dT .M a t s u m i y a ,“ F o r m a t i o nm e c h -
anisms of stress adaptation: role of functional coupling
of glucocorticoids and brain serotonergic nervous system,”
Nihon Shinkei Seishin Yakurigaku Zasshi, vol. 20, pp. 83–91,
2000.
[39] M. Colla, G. Kronenberg, M. Deuschle et al., “Hippocampal
volume reduction and HPA-system activity in major depres-
sion,” Journal of Psychiatric Research, vol. 41, no. 7, pp. 553–
560, 2007.
[40] J. Herbert, I. M. Goodyer, A. B. Grossmanet al., “Do corticos-
teroids damagethe brain?” Journal of Neuroendocrinology,v o l .
18, no. 6, pp. 393–411, 2006.
[41] R. M. Sapolsky, “Glucocorticoids and hippocampal atrophy
in neuropsychiatric disorders,” Archives of General Psychiatry,
vol. 57, no. 10, pp. 925–935, 2000.